Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026
100% of patients treated with CTA313 achieved an SRI-4 response, with half…
New World Lupus Federation Global Survey Finds 58% Know Very Little or Nothing About Lupus
Low familiarity and ongoing misconceptions underscore the need for increased education and…
